LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells $5,216,184.20 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 68,906 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LeMaitre Vascular Stock Down 1.2 %

Shares of LMAT stock traded down $0.90 during trading on Wednesday, reaching $75.00. 109,442 shares of the company’s stock were exchanged, compared to its average volume of 122,731. The firm’s fifty day moving average price is $66.47 and its 200-day moving average price is $59.23. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $76.24. The stock has a market capitalization of $1.68 billion, a PE ratio of 50.26, a PEG ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same quarter in the previous year, the firm earned $0.27 earnings per share. The business’s quarterly revenue was up 13.6% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.85%. LeMaitre Vascular’s payout ratio is currently 42.38%.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently modified their holdings of the company. BluePath Capital Management LLC bought a new position in LeMaitre Vascular in the 3rd quarter valued at about $31,000. YHB Investment Advisors Inc. purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $36,000. DekaBank Deutsche Girozentrale purchased a new stake in LeMaitre Vascular in the 3rd quarter valued at $38,000. SRS Capital Advisors Inc. lifted its stake in LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 524 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in LeMaitre Vascular during the 1st quarter worth $206,000. 84.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on LMAT shares. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. JMP Securities upped their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday, May 3rd. Barrington Research raised their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. KeyCorp started coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price target for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $73.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.